The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Management of glioblastoma: State of the art and future directions
Open accessAbstract
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. The standard approach to therapy in the newly diagnosed setting includes surgery followed by concurrent radiotherapy with temozolomide and further adjuvant temozolomide. Tumor‐treating fields, delivering low‐intensity alternating electric fields, can also be given concurrently with adjuvant temozolomide. At recurrence, there is no standard of care; however, surgery, radiotherapy, and systemic therapy with chemotherapy or bevacizumab are all potential options, depending on the patient's circumstances. Supportive and palliative care remain important considerations throughout the disease course in the multimodality approach to management. The recently revised classification of glioblastoma based on molecular profiling, notably isocitrate dehydrogenase ( IDH ) mutation status, is a result of enhanced understanding of the underlying pathogenesis of disease. There is a clear need for better therapeutic options, and there have been substantial efforts exploring immunotherapy and precision oncology approaches. In contrast to other solid tumors, however, biological factors, such as the blood‐brain barrier and the unique tumor and immune microenvironment, represent significant challenges in the development of novel therapies. Innovative clinical trial designs with biomarker‐enrichment strategies are needed to ultimately improve the outcome of patients with glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationComprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy131 · Cited by 2,138
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Shaw, E., Scott, C., Souhami, L., Dinapoli, R., Kline, R., Loeffler, J., & Farnan, N. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00507-6 · Cited by 1,608
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Radiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E. B., Suki, D., Sawaya, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1373 · Cited by 1,081
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
The anatomical and cellular basis of immune surveillance in the central nervous system
Ransohoff, R. M., & Engelhardt, B. (2012) · Nature Reviews Immunology · doi:10.1038/nri3265 · Cited by 972
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Senft, C., Bink, A., Franz, K., Vatter, H., Gasser, T., & Seifert, V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70196-6 · Cited by 826
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Self-citationRadiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Radiation Dose–Volume Effects in the Brain
Lawrence, Y. R., Li, X. A., el Naqa, I., Hahn, C. A., Marks, L. B., Merchant, T. E., & Dicker, A. P. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.091 · Cited by 753
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Glioblastoma survival in the United States before and during the temozolomide era
Johnson, D. R., & O’Neill, B. P. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0749-4 · Cited by 720
Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014
Ostrom, Q. T., Cote, D. J., Ascha, M., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1789 · Cited by 614
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Longitudinal molecular trajectories of diffuse glioma in adults
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 561
Self-citationPrognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
Lamborn, K. R., Chang, S. M., & Prados, M. D. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000620 · Cited by 546
Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1507-6 · Cited by 537
Fisher, J. L., Schwartzbaum, J. A., Wrensch, M., & Wiemels, J. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.002 · Cited by 528
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Chaichana, K. L., Jusue-Torres, I., Navarro-Ramirez, R., Raza, S. M., Pascual-Gallego, M., Ibrahim, A., Hernandez-Hermann, M., Gomez, L., Ye, X., Weingart, J. D., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not137 · Cited by 505
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Koshy, M., Villano, J. L., Dolecek, T. A., Howard, A., Mahmood, U., Chmura, S. J., Weichselbaum, R. R., & McCarthy, B. J. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0738-7 · Cited by 481
Maximizing safe resection of low- and high-grade glioma
Hervey-Jumper, S. L., & Berger, M. S. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2110-4 · Cited by 471
Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428
Lombardi, G., De Salvo, G. L., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Gutin, P. H., Iwamoto, F. M., Beal, K., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S., Yamada, Y., Chang, J., & Abrey, L. E. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.043 · Cited by 370
Corticosteroids compromise survival in glioblastoma
Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S., Dai, C., Ozawa, T., Chang, M., Chan, T. A., et al. (2016) · Brain · doi:10.1093/brain/aww046 · Cited by 363
Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
Han, S., Zhang, C., Li, Q., Dong, J., Liu, Y., Huang, Y., Jiang, T., & Wu, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.162 · Cited by 355
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 350
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Fogh, S. E., Andrews, D. W., Glass, J., Curran, W., Glass, C., Champ, C., Evans, J. J., Hyslop, T., Pequignot, E., Downes, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6941 · Cited by 347
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Heimberger, A. B., Abou-Ghazal, M., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 332
Gromeier, M., Alexander, L., & Wimmer, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2370 · Cited by 330
Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox036.071 · Cited by 325
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Stummer, W., Tonn, J.-C., Mehdorn, H. M., Nestler, U., Franz, K., Goetz, C., Bink, A., & Pichlmeier, U. (2011) · Journal of Neurosurgery · doi:10.3171/2010.3.jns097 · Cited by 300
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
Histologic classification of gliomas
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802997-8.00005-0 · Cited by 297
European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, E. L., Grant, R., Oliver, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 297
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Di Stefano, A. L., Fucci, A., Frattini, V., Labussiere, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2199 · Cited by 293
Karremann, M., Gielen, G. H., Hoffmann, M., Wiese, M., Colditz, N., Warmuth-Metz, M., Bison, B., Claviez, A., van Vuurden, D. G., von Bueren, A. O., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox149 · Cited by 293
Atopy and Risk of Brain Tumors: A Meta-analysis
Linos, E., Raine, T., Alonso, A., & Michaud, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm170 · Cited by 275
Ringel, F., Pape, H., Sabel, M., Krex, D., Bock, H. C., Misch, M., Weyerbrock, A., Westermaier, T., Senft, C., Schucht, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov145 · Cited by 267
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f9c5e · Cited by 260
Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M. C., Herrlinger, U., Ketter, R., Schlegel, U., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 254
PERRY, J. R., JULIAN, J. A., LAPERRIERE, N. J., GEERTS, W., AGNELLI, G., ROGERS, L. R., MALKIN, M. G., SAWAYA, R., BAKER, R., FALANGA, A., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03973.x · Cited by 249
Cabrera, A. R., Kirkpatrick, J. P., Fiveash, J. B., Shih, H. A., Koay, E. J., Lutz, S., Petit, J., Chao, S. T., Brown, P. D., Vogelbaum, M., et al. (2016) · Practical Radiation Oncology · doi:10.1016/j.prro.2016.03.007 · Cited by 246
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
Simon, M., Hosen, I., Gousias, K., Rachakonda, S., Heidenreich, B., Gessi, M., Schramm, J., Hemminki, K., Waha, A., & Kumar, R. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou158 · Cited by 237
Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007
Leece, R., Xu, J., Ostrom, Q. T., Chen, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox091 · Cited by 235
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
Symptoms and problems in the end-of-life phase of high-grade glioma patients
Sizoo, E. M., Braam, L., Postma, T. J., Pasman, H. R. W., Heimans, J. J., Klein, M., Reijneveld, J. C., & Taphoorn, M. J. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop045 · Cited by 215
Efficacy of anti-epileptic drugs in patients with gliomas and seizures
Breemen, M. S. M., Rijsman, R. M., Taphoorn, M. J. B., Walchenbach, R., Zwinkels, H., & Vecht, C. J. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5156-9 · Cited by 201
Taphoorn, M. J. B., Dirven, L., Kanner, A. A., Lavy-Shahaf, G., Weinberg, U., Taillibert, S., Toms, S. A., Honnorat, J., Chen, T. C., Sroubek, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5082 · Cited by 201
Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J.-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 198
Review on Quality of Life Issues in Patients with Primary Brain Tumors
Taphoorn, M. J. B., Sizoo, E. M., & Bottomley, A. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0291 · Cited by 189
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., O'Rourke, D. M., Tran, D. D., Fink, K. L., Nabors, L. B., Li, G., Bota, D. A., Lukas, R. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1140 · Cited by 187
Tumor treating fields: A novel treatment modality and its use in brain tumors
Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now182 · Cited by 177
Ma, D. J., Galanis, E., Anderson, S. K., Schiff, D., Kaufmann, T. J., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou328 · Cited by 171
Wen, P. Y., Touat, M., Alexander, B. M., Mellinghoff, I. K., Ramkissoon, S., McCluskey, C. S., Pelton, K., Haidar, S., Basu, S. S., Gaffey, S. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01207 · Cited by 169
Chowdhary, S. A., Ryken, T., & Newton, H. B. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1724-2 · Cited by 167
Medical management of brain tumors and the sequelae of treatment
Schiff, D., Lee, E. Q., Nayak, L., Norden, A. D., Reardon, D. A., & Wen, P. Y. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou304 · Cited by 161
Anti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 159
Self-citationWick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., Taphoorn, M. J. B., Steuve, J., Brandes, A. A., Hamou, M.-F., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 159
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Lukas, R. V., Rodon, J. A., Becker, K. P., Wong, E. T., Shih, K. C., Touat, M., Fassò, M., Osborne, S., Molinero, L. L., O'Hear, C. E., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2955-9 · Cited by 154
Bevacizumab and daily temozolomide for recurrent glioblastoma
Desjardins, A., Reardon, D. A., Sykes, A. D., Marcello, J. E., Herndon, J. E., Bailey, L., Peters, K. B., Friedman, H. S., & Vredenburgh, J. J. (2011) · Cancer · doi:10.1002/cncr.26381 · Cited by 149
Self-citationSafety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Yung, W. K. A., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P. L., Klencke, B. J., GILBERT, M. R., Reardon, D. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq072 · Cited by 140
The interface between glial progenitors and gliomas
Canoll, P., & Goldman, J. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0432-9 · Cited by 133
Amirian, E. S., Zhou, R., Wrensch, M., Olson, S. H., Scheurer, M. E., Il’yasova, D., Lachance, D. H., Armstrong, G., Mccoy, L. S., Lau, C. C., et al. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0847 · Cited by 128
Heimberger, A. B., Sun, W., Hussain, S. F., Dey, M., Crutcher, L. M., Aldape, K., Gilbert, M. R., Hassenbusch, S. J., Sawaya, R. A., Schmittling, B., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-046 · Cited by 126
Weller, M., Kaulich, K., Hentschel, B., Felsberg, J., Gramatzki, D., Pietsch, T., Simon, M., Westphal, M., Schackert, G., Tonn, J. C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28576 · Cited by 119
Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study
Zawlik, I., Vaccarella, S., Kita, D., Mittelbronn, M. G. A., Franceschi, S., & Ohgaki, H. (2008) · Neuroepidemiology · doi:10.1159/000170088 · Cited by 111
Environmental risk factors of primary brain tumors: A review
Vienne-Jumeau, A., Tafani, C., & Ricard, D. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.004 · Cited by 110
Gramatzki, D., Roth, P., Rushing, E. J., Weller, J., Andratschke, N. H., Höfer, S., Korol, D., Regli, L., Pangalu, A., Pless, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy106 · Cited by 105
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Ferguson, S. D., Zhou, S., Huse, J. T., de Groot, J., Xiu, J., Subramaniam, D. S., Mehta, S. V., Gatalica, Z., Swensen, J. J., Sanai, N., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly022 · Cited by 103
Cabrera, A. R., Cuneo, K. C., Desjardins, A., Sampson, J. H., McSherry, F., Herndon, J. E., Peters, K. B., Allen, K. J., Hoang, J. K., Chang, Z., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.029 · Cited by 98
Self-citationAbhinav, K., Yeh, F.-C. F., Mansouri, A., Zadeh, G. M., & Fernandez-Miranda, J. C. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov113 · Cited by 90
Pallud, J., Audureau, É., Noël, G., Corns, R. A., Lechapt, E., Duntze, J., Pavlov, V., Guyotat, J., Hieu, P. D., Reste, P. L., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov126 · Cited by 90
PCV chemotherapy for recurrent glioblastoma
Schmidt, F., Fischer, J., Herrlinger, U., Dietz, K., DICHGANS, J., & Weller, M. (2006) · Neurology · doi:10.1212/01.wnl.0000197792.73656.c2 · Cited by 89
Weller, M., Rhun, É. L., Preusser, M., Tonn, J., & Roth, P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000520 · Cited by 87
Shah, N., Lankerovich, M., Lee, H., Yoon, J., Schroeder, B., & Foltz, G. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-818 · Cited by 86
Nava, F., Tramacere, I., Fittipaldo, V. A., Bruzzone, M. G., DiMeco, F., Fariselli, L., Finocchiaro, G., Pollo, B., Salmaggi, A., Silvani, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not316 · Cited by 85
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84
Berntsen, E. M., Gulati, S., Solheim, O. S., Kvistad, K. A., TORP, S. H., Selbekk, T., Unsgård, G., & Haberg, A. K. (2010) · Neurosurgery · doi:10.1227/01.neu.0000371731.20246.ac · Cited by 81
Hutterer, M., Nowosielski, M., Haybaeck, J., Embacher-Aichhorn, S., Stockhammer, F., Gotwald, T., Holzner, B., Capper, D., Preusser, M., Marosi, C., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not161 · Cited by 80
Drilon, A. E. D. C., DuBois, S. G., Farago, A. F., Geoerger, B., Grilley‐Olson, J. E., Hong, D. S., Sohal, D. P. S., van Tilburg, C. M., Ziegler, D. S., Ku, N. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2006 · Cited by 79
Brindle, K. M., Izquierdo-García, J. L., Lewis, D. Y., Mair, R. J., & Wright, A. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7636 · Cited by 75
Demetri, G. D., Paz-Ares, L. G., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.017 · Cited by 71
Eigenbrod, S., Trabold, R., Brucker, D., Erös, C., Egensperger, R., la Fougère, C. J., Göbel, W., Rühm, A., Kretzschmar, H. A., Tonn, J. C., et al. (2014) · Acta Neurochirurgica · doi:10.1007/s00701-014-2073-1 · Cited by 65
Jungk, C., Chatziaslanidou, D., Ahmadi, R., Capper, D., Bermejo, J. L., Exner, J., von Deimling, A., Herold‐Mende, C. C., & Unterberg, A. W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2131-6 · Cited by 65
Chandramohan, V., Bryant, J. D., Piao, H., Keir, S. T., Lipp, E., Lefaivre, M., Perkinson, K. R., Bigner, D. D., Gromeier, M., & McLendon, R. E. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0580-oa · Cited by 59
Bénit, C. P., & Vecht, C. J. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv038 · Cited by 55
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Wick, A., Keßler, T., Elia, A. E. H., Winkler, F., Batchelor, T. T., Platten, M., & Wick, W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox133 · Cited by 55
Dixit, S., Hingorani, M., Achawal, S., & Scott, I. S. (2011) · British Journal of Neurosurgery · doi:10.3109/02688697.2010.550342 · Cited by 41
The involvement of thrombin in the pathogenesis of glioblastoma
Krenzlin, H., Lorenz, V., & Alessandri, B. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24049 · Cited by 32
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study
Carvalho, B., Fernandes, A. C., Almeida, D. S., Sampaio, L., Costa, A., Caeiro, C., Osório, L., Castro, L., Linhares, P., Damasceno, M., et al. (2015) · Oncology Research and Treatment · doi:10.1159/000431236 · Cited by 26
Badruddoja, M., Pazzi, M., Sanan, A., Schroeder, K., Kuzma, K., Norton, T., Scully, T., Mahadevan, D., & Malek‐Ahmadi, M. H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3405-7 · Cited by 26
Lassman, A. B., Pugh, S. L., Wang, T., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz175.064 · Cited by 25
NovoTTF: where to go from here?
Cloughesy, T. F., & Lassman, A. B. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox014 · Cited by 19
Cited by
The role of m6A modification in the biological functions and diseases
Jiang, X., Liu, B., Nie, Z., Duan, L., Xiong, Q., Jin, Z., Yang, C., & Chen, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00450-x · Cited by 2,335
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Emerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.050 · Cited by 431
Glioblastoma: clinical presentation, diagnosis, and management
McKinnon, C., Nandhabalan, M., Murray, S. A., & Plaha, P. (2021) · BMJ · doi:10.1136/bmj.n1560 · Cited by 391
Metadata
- Authors
- Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2020-06
- Volume
- 70
- Issue
- 4
- Pages
- 299-312
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W3031224726
- Cited by
- 1,972
- References
- 143
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.